FLUOROPHARMA MEDICAL, INC. - FORM 10-K - EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 1350. - March 30, 2016

Attached files

file filename
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.ex31-2.htm
10-K - FORM 10-K - FLUOROPHARMA MEDICAL, INC.fpmi10k_dec312015.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934. - FLUOROPHARMA MEDICAL, INC.ex31-1.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 1350. - FLUOROPHARMA MEDICAL, INC.ex32-2.htm
EX-23.1 - CONSENT OF WOLF & COMPANY, P.C. - FLUOROPHARMA MEDICAL, INC.ex23-1.htm
Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
        In connection with the Annual Report of FluoroPharma Medical, Inc. (the "Company") on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas H. Tulip, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company


March 30, 2016
/s/ Thomas H. Tulip
Thomas H. Tulip, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)

FLUOROPHARMA MEDICAL, INC. Reports